Salazar-Marcelino AE, Herrera-García JC, Toledo-Estrada J, Mendoza-Torres MÁ, Romero-Ogawa T

Language: Spanish
References: 28
Page: 3-8
PDF size: 480.17 Kb.

ABSTRACT

Background: Hepatopulmonary syndrome is one of the least frequent extrahepatic manifestations of hepatic failure. Its incidence is of 13% to 47%, with survival of 40% to 2.5 years.
Objective: To describe the prevalence of hepatopulmonary syndrome in Mexican patients with cirrhosis, as well as its clinical characteristics.
Material and Method: A descriptive, observational, longitudinal and ambilective study was done including patients from Liver Clinic, with diagnosis of cirrhosis in clinical surveillance. The diagnosis of hepatopulmonary syndrome was considered in presence of alveolar/ arterial gradient › 15 mmHg and vascular dilatation assessed by contrast echocardiography and tests of respiratory function by the Neumology Department of Specialties Hospital 5 de Mayo, ISSSTEP, Puebla, Mexico, from March to August 2014.
Results: Ninety-four patients were included. It was determined hepatopulmonary syndrome in 4/94 patients. The most prevalent cause was non-alcoholic hepatic disease in 35%, alcohol-related in 24%, viral in 16% and other causes in 25%. The most frequent symptoms associated with hepatopulmonary syndrome were: dyspnea, thoracic pain and chronic cough. All patients with hepatopulmonary syndrome had hypoxemia in different degrees. Severity of disease catalogued by Child-Pugh did not determine the appearance of symptoms.
Conclusions: Hepatopulmonary syndrome affects 4% of cirrhotic patients, who had hypoxemia and elevation of the alveolar/arterial gradient. Severity of hepatic disease does not determine the appearance of the disease. Its opportune detection reduces mortality of patients.

REFERENCES

1. Hemprich U, et al. Respiratory failure and hypoxemia in the cirrhotic patient including hepatopulmonary syndrome. Curr Opin Anaesthesiol 2010;23:133-138.

2. Martínez. Síndrome hepatopulmonar. An Med (Mex) 2006;51:124-133.

3. Zagolín M, Medel JN, Valera J. Síndrome hepatopulmonar e hipertensión portopulmonar: Dos entidades a diferenciar. Revista Chilena de Enfermedades Respiratorias 2008;24:291-303.

4. Shijo M, Sasaki H, Sakata H, Kusuhara H, et al. Reversibility of hepatopulmonary syndrome evidenced by serial pulmonary perfusion scan. Gastroenterol Jpn 1993;2S:126-131.

5. Zagolín B. Síndrome hepatopulmonar e hipertensión portopulmonar: Dos entidades a diferenciar. Rev Chil Enf Respir 2008;24:291-303.

6. World Gastroenterology Organisation, 2012.

7. Buey. Cirrosis hepática. Medicine 2012;11:625-633.

8. Swanson K, Wiesner R, Krowka M. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005;41:1122-1129.

9. Zhang Z, Qing Ch. Progress in investigating the pathogenesis of hepatopulmonary syndrome. Hepatobiliary Pancreat Dis Int August 2010;9:355-360.

10. Zhang. Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol 2012;9:539-549.

11. Carrillo. Síndrome hepatopulmonar. Rev Fac Med UNAM 2001;44.

12. Rodríguez A. Liver-induced lung vascular disorder. N Engl J Med 2008;358:2378-2387.

13. Monsel A, Mal H, Brisson H, Luo R, et al. Extracorporeal membrane oxygenation as a bridge to liver transplantation for acute respiratory distress syndrome induced lifethreatening hypoxaemia aggravated by hepatopulmonary syndrome. Critical Care 2011;15:1-6.

14. Muñoz S, Bardi A, Sapunar J, Antolini M. Síndrome hepatopulmonar. Revista HCUCh 2006;17:229-237.

15. Shijo H, Nakayama K, Sasaki H, Ueki T, et al. Reversibility of pulmonary telangiectasia in liver cirrhosis evidenced by serial dynamic pulmonary perfusion imaging. Clin Nucl Med 1989; 14: 909-911.

16. Herve P, et al. Pulmonary vascular abnormalities in cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:141-159.

17. Schenk P, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 2002;51:853-859.

18. Rodríguez-Roisin R y col. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24:861-880.

19. Varghese J, et al. Hepatopulmonary syndrome-past to present. Ann Hepatol 2007;6:135-142.

20. Uribe M, et al. Epidemiología, fisiopatología y diagnóstico de la hipertensión arterial pulmonar (HAP) en el cirrótico. Gac Méd Méx 2012;148:153-161.

21. Fallon MB, et al. The lung in liver disease: old problem, new concepts. Trans Am Clin Climatol Assoc 2013;124:250-262.

22. Fallon MB, Krowka MJ, Brown RS, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008;135:1168- 1175.

23. Shafiq M, Khan AA, Alam A, Butt AK, et al. Frequency of hepatopulmonary syndrome in cirrhotic patients. J Coll Physicians Surg Pak 2008;18:278-281.

24. Porres-Aguilar M. Complicaciones pulmonares vasculares en hipertensión portal y enfermedad hepática: una revisión concisa. Rev Gastroenterol Méx 2013;78:35-44.

25. Schenk P, Schöniger-Hekele M, Fuhrmann V, Madl C, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003;125:1042-1052.

26. El Makarem EA, et al. Hepatopulmonary syndrome: prevalence and predictors in Egyptian cirrhotic patients. Trop Gastroenterol 2011;32:25-30.

27. Zhang J, Luo B, Tang L, et al. Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology 2009;136:1070-1080.

28. Roberts DN, Arguedas MR, Fallon MB. Cost-effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates. Liver Transpl 2007;13:206-214.